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The temporal pattern of changes in 
serum biomarker levels reveals 
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pathologies after exposure to a 
single low-intensity blast in mice
Farid Ahmed1, Stefan Plantman2, Ibolja Cernak3† and Denes V. Agoston1,2*†
1 Department of Anatomy, Physiology and Genetics, Uniformed Services University, Bethesda, MD, USA, 2 Department of 
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Time-dependent changes in blood-based protein biomarkers can help identify the 
 pathological processes in blast-induced traumatic brain injury (bTBI), assess injury severity, 
and monitor disease progression. We obtained blood from control and injured mice 
(exposed to a single, low-intensity blast) at 2-h, 1-day, 1–week, and 1-month post-injury. 
We then determined the serum levels of biomarkers related to metabolism (4-HNE, HIF-1α, 
ceruloplasmin), vascular function (AQP1, AQP4, VEGF, vWF, Flk-1), inflammation (OPN, 
CINC1, fibrinogen, MIP-1a, OX-44, p38, MMP-8, MCP-1 CCR5, CRP, galectin-1), cell 
adhesion and the extracellular matrix (integrin α6, TIMP1, TIMP4, Ncad, connexin-43), 
and axonal (NF-H, Tau), neuronal (NSE, CK-BB) and glial damage (GFAP, S100β, MBP) 
at various post-injury time points. Our findings indicate that the exposure to a single, 
low-intensity blast results in metabolic and vascular changes, altered cell adhesion, and 
axonal and neuronal injury in the mouse model of bTBI. Interestingly, serum levels of several 
inflammatory and astroglial markers were either unchanged or elevated only during the 
acute and subacute phases of injury. Conversely, serum levels of the majority of biomarkers 
related to metabolic and vascular functions, cell adhesion, as well as neuronal and axonal 
damage remained elevated at the termination of the experiment (1 month), indicating long-
term systemic and cerebral alterations due to blast. Our findings show that the exposure to 
a single, low-intensity blast induces complex pathological processes with distinct temporal 
profiles. Hence, monitoring serum biomarker levels at various post-injury time points may 
provide enhanced diagnostics in blast-related neurological and multi-system deficits.
Keywords: blast, traumatic brain injury, mouse, serum, biomarkers
introduction
The mild form of traumatic brain injury (mTBI, also called concussion) accounts for ~75% of all head 
injuries among civilians and military personnel (1, 2). In the U.S. military, mTBI, mostly caused by 
explosive weaponry, has affected ~300,000–500,000 military personnel during the last 15 years (3–5). 
Numerous terms, including blast-induced neurotrauma (BINT) (3, 4), blast-induced TBI, or just 
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blast TBI (bTBI), have been coined to describe the unique clinical 
entity of blast-induced neurological deficits caused by interwoven 
mechanisms of systemic, local, and cerebral responses to blast 
exposure(s) (4, 5).
Similar to civilian concussion, the acute symptoms of mild, 
blast-induced TBI (mbTBI) are usually mild and transient (6). 
However, in addition to the large number of affected individuals, 
mbTBI is a significant health issue for several reasons. Repetitive 
mild injuries – if they occur within the period of increased cer-
ebral vulnerability – can result in a disproportionally severe acute 
outcome (7, 8). Moreover, mbTBI, especially when repeated, could 
significantly increase the probability of late onset neurodegenera-
tive conditions, such as chronic traumatic encephalopathy (CTE) 
(9, 10). Finally, blast interacting with the entire body and not only 
with the head, induces complex co-occurring systemic, local, 
and cerebral responses to injury (11–14). Thus, the neurological 
deficits that develop after blast exposure(s) are resulted not only 
from the brain damage caused via head-blast interaction but also 
from multiple, synergistically acting injury mechanisms. Because 
of such complexity, the diagnosis of blast-induced neurological 
consequences, both during the acute and chronic injury phases, 
is extremely challenging: the manifestations of mbTBI are often 
masked by symptoms of systemic changes.
It is noteworthy that many of the acute and subacute neu-
robehavioral symptoms of mbTBI, such as impaired cognition 
and emotional instability, are shared with post-traumatic stress 
disorder (PTSD), a complex clinical syndrome triggered by 
extreme psychological stress without physical injury (15). Since 
the diagnosis of mbTBI and PTSD are often solely based on 
neuropsychological tests and self-reported information, the dif-
ferential diagnosis is challenging due to the absence of objective 
outcome measures. While earlier studies using rodent models 
have suggested that the pathobiology of PTSD and mbTBI may 
involve distinct mechanisms (15–18), the precise identities of the 
molecular events leading to the observed functional changes are 
still unclear (19).
The increasing numbers of research studies using various 
animal models, in combination with analytical techniques such 
as histopathology and proteomics, have identified some of the 
mechanisms underlying the pathology of bTBI. These findings 
include metabolic and vascular changes; axonal, neuronal and glial 
damage; inflammation; and altered cell adhesion, among others 
(13, 20–29). In this study, we used the previously developed, well-
standardized, and validated mouse model of primary blast injuries 
(30), which reproduces the main consequences of blast exposures: 
changes in general physiology, multi-organ damages, systemic 
compensatory mechanisms, as well as neurological deficits seen in 
individuals exposed to differing blast intensity levels. Our intention 
was to reproduce the full spectrum of injury response mechanisms 
induced by primary blast and not only head trauma as an isolated 
entity (30, 31). Previous works with this model has determined 
that the vital functions, memory and cognitive performance, 
and behavioral impairments are comparable with the symptoms 
of mild and moderate TBI in war fighters exposed to blast (30, 
31). Those findings also implicated inflammation as a potential 
mechanistic explanation for the long-term neurological deficits 
after blast exposure.
Using the same mouse model of bTBI (30, 31), we determined 
changes in the serum levels of protein biomarkers at 2 h, 1 day, 
1 week, and 1 month after exposure. We selected 31 biomarkers 
indicative of changes in metabolic and vascular functions; cell 
adhesion; axonal, neuronal, and glial integrities; and inflamma-
tion to determine the temporal pattern of changes from early/
acute (2 h) to late/chronic (1 month) post-injury time points. We 
found that the exposure to low-intensity blast triggers complex 
changes in serum levels of biomarkers, many of them remain-
ing highly elevated at 1 month after the injury suggesting that a 
single exposure to low-intensity blast can induce lasting molecular 
pathologies. Our findings have implications for determining the 
period of ICV after mbTBI, and identifying the distinct pathologies 
that involve a widespread systemic response in the pathobiology 
of blast-induced neurological deficits. Moreover, our results 
underline the role of long-term monitoring of serum protein 
biomarkers in the differential diagnosis between mbTBI and PTSD 
as well as mbTBI and impact TBI. As such, our findings imply that 
continuous assessments of serum protein biomarkers could help 
in predicting the outcome of mbTBI and preempting multi-organ 
complications of blast exposure.
Materials and Methods
All protocols involving the use of animals complied with the Guide 
and Care and Use of laboratory Animals published by the NIH 
(DHEW publication NIH 85-23-2985) and were approved by the 
Johns Hopkins University Animal Use Committee. Exposures 
were performed at the Johns Hopkins University Applied Physics 
Laboratory (JHU/APL) using a modular, multi-chamber shock 
tube capable of reproducing complex shock wave signatures seen 
in theater (30, 31).
Blast injury
Twenty-five 3–4-month-old C57/B16 mice (Jackson Laboratories) 
were used. Animals (weighing 22–24 g at the beginning of the 
study) were divided into three experimental groups: naïve 
(n =  5), sham (n =  5), and injured (n =  20). Animals were 
housed in pairs in standard mouse cages in a reverse 12 h light 
and 12 h dark cycle with access to food and water ad libitum. 
Animals in the sham and in the injured groups were anesthetized 
with 4% isoflurane evaporated in a gas mixture containing 30% 
oxygen/70% nitrous oxide and applied through a nose mask. The 
animals were allowed to breathe spontaneously without tracheal 
intubation. Mice were then mounted in a supine position to the 
animal holder and placed in the shock tube as described (30). 
The animal holder positioned the specimen at 53 cm (20.87˝) 
upstream from the driven section opening, so that only a well-
formed incident shock wave loaded the animal and potential 
rarefactions from the tube opening were minimized. The neck, 
head, torso, and abdomen of the animal were fixed to the animal 
holder to avoid any movement, thus eliminating tertiary blast 
effects. The loading conditions (mean ± SD) were the follow-
ing: measured membrane rupture pressure 19.2  ±  2.7  psig 
(132.38 ± 18.62 kPag); measured static pressure 7.5 ± 1.1 psig 
(51.71 ± 7.58 kPag); time pressure rise 0.010284 ± 0.000964 s; 
time pressure fall 0.0048 ± 0.0027; and pulse width 15.3 ± 2.9 ms. 
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Sham animals were handled identically except exposure to the 
pressure wave.
Body Weight
Measurements were performed at baseline, and at 1-day, 3-day, 
5-day, 1-week, and 1-month post-injury.
acute neurological Outcome
Neurological outcome was evaluated immediately after exposure 
by observing the spontaneous behavior of the animal and by 
assessing the tail pinch reflex (time of response to pain stimulus), 
corneal reflex (time of response to corneal touch), and righting 
reflex (time of self-correction in an animal placed on its back to 
return to its normal upright position).
Blast injury severity
The mortality rate was assessed at 24 h post-trauma. Injured mice 
were sacrificed at 2-h (n = 5), 1-day (n = 5), 1-week (n = 5), and 
1-month (n =  5) post-injury. Blast injury severity in animals 
with lethal outcome and in survival animals at the end of the 
30-day post-exposure period was performed using the Pathology 
Scoring System (PSS) for Blast Injuries (32) modified as previously 
described (12, 30, 33).
Biosamples
Animals were anesthetized with 4% isoflurane evaporated in a gas 
mixture containing 30% oxygen/70% nitrous oxide and applied 
through a nose mask. After a midline thoracic incision, the heart 
was carefully exposed and blood samples were obtained via cardiac 
puncture and collected into BD Vacutainer SST plastic serum tube 
with clot activator and gel for serum separation (Ref. 367988). The 
blood was allowed to clot at room temperature for 40 min followed 
by centrifugation at 2000 g for 15 min. Collected supernatants 
were then divided into 200 μl aliquots, flash-frozen, and stored 
at −80°C until use.
sample Preparation for reverse Phase Protein 
Microarray assay
Serum samples were manually diluted 1:10 with 3× print buffer; 
samples were further diluted using a JANUS Varispan Integrator 
and Expanded Platform Workstation (PerkinElmer, Waltham, 
MA, USA) resulting in a 11-point serial dilution in triplicates in 
384-well microarray plates (X7022; Fisher Scientific, Pittsburgh, 
PA, USA) (14, 18, 23, 34). The plates were then transferred into 
an Aushon 2470 Arrayer (Aushon Biosystems, Billerica, MA, 
USA) and printed on ONCYTE Nova single-pad nitrocellulose 
coated glass slides (Grace Bio-Labs, Bend, OR, USA). The Aushon 
2470 Arrayer was set up with 16 pins and programed for single 
deposit. The spot diameter was set to 250 nm with a spacing of 
500 nm between dots on the x-axis and 375 nm on the y-axis. Wash 
time was set at 2 s without delays. Following desiccation at 4°C 
overnight, slides were blocked with 5% non-fat dry milk in 1× TBS 
with 0.1% Tween 20 (TBST). Primary antibodies (see Table S1 in 
Supplementary Material) were diluted to 10× the optimal Western 
analysis concentration in antibody incubation buffer [0.1% BSA, 
protease inhibitors (EDTA-free Halt protease and phosphatase 
inhibitor cocktail, Thermo Fisher, Waltham, MA, USA), 1× TBS, 
0.5% Tween 20] (14, 18, 23, 34). Slides were incubated with the 
primary antibody solution overnight at 4°C covered by a cover 
slip (Nunc* mSeries LifterSlips, Fisher Scientific, Pittsburg, PA, 
USA). The following day slides were thoroughly washed three 
times with TBST (1× TBS in 0.1% Tween 20) and incubated 
with the secondary antibodies [Alexa Fluor® 635 goat anti-mouse 
(A-31574), Alexa Fluor® 647 goat anti-rabbit (A-21245), 647 rabbit 
anti-goat (A-21446) or Alexa Fluor® 633 donkey anti-sheep IgG 
(H +  L) (A-21100)] (all from Invitrogen) diluted at 1:6000 in 
antibody incubation buffer for 1  h at room temperature. After 
three thorough washes in TBST followed by a single wash with 1× 
TBS slides were air dried and the intensity of fluorescent signals 
were determined in a Scan Array Express HT microarray scanner 
(Perkin Elmer, Waltham, MA, USA) using a 633 nm wavelength 
laser and a 647 nm filter.
Data analysis
Data were imported into a Microsoft Excel-based bioinformatics 
program for analysis (14, 18, 23, 34). The program imports intensity 
data from the scanner and calculates total net intensity after local 
background subtraction (i.e., the intensities of secondary antibody 
alone and for each corresponding primary antibody) for each spot. 
Intensity data from the dilution series of each sample were then 
plotted against dilution on a log–log graph. Primary data were 
manually curated by linear regression of the log–log data and were 
plotted after the removal of flagged data. Flagged data include spot 
intensities in the saturation range or noise range, signal to noise 
ratios <2, or high variability between duplicate spots (>10–15%). 
The total amount of antigen is determined by the y-axis intercept 
or y-cept (i.e., by extrapolating the regression line to zero); reported 
values are log 10.
Differences in protein biomarker levels at each of the post-
injury time points relative to naïve levels were analyzed with 
independent t-tests. A Bonferroni-adjusted significance level of 
0.0125 was calculated to account for the increased possibility of 
type I error. Relative intensity data (y-cept values) were presented 
as the mean ± SEM. Statistical significance is reported for naïve vs. 
injured mice at each time point where applicable (Figures 1–4).
results
Body Weight
Blast exposure caused significant weight loss at days 3 and 5 after 
injury: 27.5 ± 0.65 g and 27.7 ± 0.53 g, respectively, compared to 
the pre-injury value of 29.3 ± 0.35 g. The body weight (BW) of 
injured mice was normalized 1 week after the exposure.
acute neurological Outcome
Following the cessation of anesthesia, control mice recovered the 
tail pinch reflex after a mean 1.65 ± 0.15 min, corneal reflex after 
1.86 ± 0.17 min, and righting reflex after 2.73 ± 0.25 min. The blast 
exposure somewhat extended the time needed for reflex recovery 
(tail pinch reflex: 2.43 ± 1.37 min; corneal reflex: 3.37 ± 2.13 min; 
and righting reflex: 3.42 ± 2.02 min). Nevertheless, these changes 
were not statistically significant due to relatively large variations 
between animals.
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Blast injury severity
The mortality rate at 24  h after exposure was 4.5%, which is 
comparable to the 5% mortality rate in animals exposed to 
mild intensity blast reported in our previous study (30). Death 
occurred immediately, mostly due to cardiorespiratory depres-
sion and did not correspond to any organ damage. In our cur-
rent study, the total blast injury severity score was 22.25 ± 3.11 
PSS compared to 24.44 ± 0.50 PSS in our original paper (30). 
Morphological damage in the form of slight petechiae and rare 
ecchymosis were mainly found in the lungs of exposed mice. 
Gross pathological observation of the brains following mild blast 
injury showed an absence of subarachnoid hemorrhage, focal 
lesions, or contusions.
Figure 1 | Temporal changes of select oxidative stress and vascular 
markers in serum obtained from naïve and at 2 h, 1 day, 1 week, and 
1 month of post-blast over pressure exposed animals. Protein levels of 
oxidative stress markers 4-HNE (a), HIF-1α (B), ceruloplasmin (c), vascular 
related biomarkers AQP1 (D), AQP4 (e), VEGF (F), vWF (g), and FLK-1 (h) 
were assayed using reverse phase protein microarray (RPPM) and are 
expressed as y-cept values (log 10). Data are presented as the mean ± SEM; 
**p < 0.01, ***p < 0.001.
general Biomarker Trends
We found no significant differences in serum biomarker levels 
between naïve and sham animals. However, the exposure to a single, 
 low-intensity blast resulted in substantial changes in the serum levels 
of a number of biomarkers indicating changes in metabolic and vascu-
lar functions, altered cell adhesion, as well as neuronal, axonal, and glial 
damage. Interestingly, serum levels of the majority of  inflammatory 
and astroglial markers did not change, while other biomarkers 
showed distinct temporal patterns (summarized in Table 1).
Metabolic and Vascular Markers
Of the three metabolic and oxidative stress markers, ceruloplas-
min showed the highest initial increase at 2 h compared to naïve 
Figure 2 | Temporal changes of select inflammatory markers in 
serum obtained from naïve and at 2 h, 1 day, 1 week, and 1 month of 
post-blast over pressure exposed animals. Protein levels of OPN (a), 
CINC1 (B), fibrinogen (c), MIP-1α (D), OX-44 (e), p38 (F), MMP-8 (g), 
MCP-1 (h), CCR5 (i), CRP (J), and galectin-1 (K) were assayed using 
reverse phase protein microarray (RPPM) and are expressed as y-cept 
values (log 10). Data are presented as the mean ± SEM; **p < 0.01, 
***p < 0.001.
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Figure 3 | Temporal changes of select cell surface markers in serum 
obtained from naïve and at 2 h, 1 day, 1 week, and 1 month of 
post-blast over pressure exposed animals. Protein levels of integrin 6α (a), 
TIMP1 (B), TIMP4 (c), Ncad (D), and Connexin-43 (e) were assayed using 
reverse phase protein microarray (RPPM) and are expressed as y-cept values 
(log 10). Data are presented as the mean ± SEM; **p < 0.01, ***p < 0.001.
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levels; serum levels continued to increase reaching a maximum 
at 1-month post-injury (Figure  1C). HIF-1α levels were high-
est at 2  h post-injury, remaining elevated up to 1  month after 
injury (Figure 1B). 4-HNE serum levels were highest at 1 day and 
1-month post-injury (Figure 1A).
Of the markers related to vascular function, serum levels of 
AQP1, VEGF, and vWF showed the most substantial increases 
in response to injury, each displaying a distinct temporal pattern 
(Figures 1D,F,G). The changes in VEGF levels showed a bi-phasic 
profile. After an initial peak at 2 h, VEGF levels returned close to 
normal before peaking again at 1-month post-injury (Figure 1F). 
vWF levels were highest 1 day post-exposure and while serum 
levels declined over time, they were still significantly higher than 
naïve values 1 month after the injury. Serum concentrations of 
the other vascular marker, Flk-1, showed an early increase at 2 h 
that was somewhat sustained at 1 day; by 1 wk levels returned to 
normal, control values. We found no significant increase in serum 
AQP4 levels at any post-injury time points (Figure 1E).
inflammatory Markers
Serum levels of a few inflammatory markers, OPN, fibrinogen, 
OX-44, and p38, increased rapidly after injury; marker levels 
(except OPN) returned to control values at or close to their peak 
level at 1-month post-injury (Figures 2A,C,E,F). The serum levels 
of CINC1 and MIP-1α (Figures 2B,D) were increased only at 1 day 
or 1 week after injury then decreased at 1 month.
Serum levels of MMP-8, MCP-1, CCR5, CRP, and galectin-1 
(Figures 2G–K) did not change significantly compared to control 
values.
cell adhesion and extracellular Matrix Markers
Serum concentrations of all cell adhesion proteins but Ncad 
increased in response to the injury, although the temporal profiles 
were different (Figure 3). Serum levels of all markers but TIMP4 
reached their maximum at 1-day post-injury and remained 
elevated until the end of the study. TIMP4 levels were highest at 
2 h after injury, decreased by 1 week, and returned to control levels 
by 1 month (Figure 3C).
axonal, neuronal, and glial Damage Markers
Serum levels of the axon- and neuron-specific markers, NF-H, 
Tau, NSE, and CK-BB, increased moderately in response to blast 
injury (Figures 4A–D). At 1 month after injury, NSE, CK-BB, 
and tau levels returned to control levels, whereas NF-H remained 
significantly elevated. Serum levels of the astroglia markers GFAP 
and S100β were not significantly increased at any of the post-
injury time points (except for a moderate elevation in S100β 
at the 1-month time point) (Figures  4E,F). Conversely, MBP 
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levels showed robust increases at 2-h and 1-week post-injury 
(Figure 4G).
Discussion
Cognitive and emotional symptoms have been consistently 
observed in soldiers exposed to blast(s). It has been reported that 
blast forces alone can cause deleterious behavioral changes when 
evaluated with selected measures of personality (35). Blast exposure 
has also been linked to self-perceived cognitive decline in soldiers 
with mbTBI (36). Recent experimental data support the notion 
that the exposure to blast (as an emotionally traumatizing event) 
can alter memory function and cause anxiety (37). Furthermore, 
it has been recognized that individuals with bTBI also suffer from 
Figure 4 | Temporal changes of select neuronal and glial damage 
markers in serum obtained from naïve and at 2 h, 1 day, 1 week, 
and 1 month of post-blast over pressure exposed animals. Protein 
levels of neuronal markers NF-H (a), NSE (B), CK-BB (c), Tau (D), glial 
markers GFAP (e), S100β (F), and MBP (g) were assayed using  
reverse phase protein microarray (RPPM) and are expressed as y-cept 
values (log 10). Data are presented as the mean ± SEM; **p < 0.01, 
***p < 0.001.
PTSD (38, 39) and that these two clinical conditions likely develop 
in parallel leading to a unique and complex clinical entity. Hence, 
the differential diagnosis between PTSD and bTBI only has merit 
if it determines distinct therapeutic approaches or if it serves to 
pre-empt bTBI complications.
The diagnosis of mild blast TBI is hugely misleading; it only 
indicates the brain’s immediate response to blast and does not take 
into account the severity of long-term complications. Nevertheless, 
without better diagnostic nomenclature, we continue to use this 
term (i.e., mbTBI) both in clinical practice and basic science 
research. Bearing in mind that there are over 300,000 veterans 
diagnosed with mbTBI, the timely diagnosis of mbTBI still remains 
an unsolved problem. Our main goal in this study was to use 
our previously standardized model and experimental set-up of 
TaBle 1 | summary of injury-induced changes in serum biomarker levels 
relative to control levels.
Markers Post-injury time points
2 h 1 day 1 week 1 month
Metabolism
4-HNE ↑ ↑ ↑ ↑
HIF-lα ↑ ↑ ↑ ↑
Ceruloplasmin ↑ ↑ ↑ ↑
Vascular function
AQP1 ↑ ↑ ↑ ↑
AQP4 Ø Ø Ø Ø
VEGF ↑ Ø ↑ ↑
vWF ↑ ↑ ↑ ↑
Flk-1 ↑ ↑ Ø Ø
inflammation
OPN ↑ ↑ Ø ↑
CINC1 Ø ↑ ↑ Ø
Fibrinogen ↑ Ø Ø Ø
MlP-lα Ø ↑ Ø Ø
OX-44 ↑ ↑ ↑ Ø
p38 ↑ ↑ Ø Ø
MMP-8 Ø Ø Ø Ø
MCP-1 Ø Ø Ø Ø
CCR5 Ø Ø Ø Ø
CRP Ø Ø Ø Ø
Galectin-1 Ø Ø Ø Ø
cell adhesion and extracellular matrix
Integrin α6 ↑ ↑ ↑ ↑
TIMP1 ↑ ↑ ↑ ↑
TIMP4 ↑ ↑ Ø Ø
Ncad Ø Ø Ø Ø
Connexin-43 ↑ ↑ ↑ ↑
axonal damage
NF-H ↑ Ø ↑ ↑
Tau ↑ ↑ Ø Ø
neuronal damage
NSE Ø ↑ ↑ Ø
CK-BB ↑ ↑ ↑ Ø
glial damage
GFAP Ø Ø Ø Ø
S100β Ø Ø Ø ↑
MBP ↑ Ø ↑ Ø
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low-intensity blast exposure generated in laboratory conditions 
to identify a set of biomarkers that would provide insight into 
the complex pathobiology of blast-induced neurological deficits 
(in this paper termed mbTBI to annotate that it was induced by 
low-intensity primary blast). Chronic elevation in serum levels 
of vascular and inflammatory biomarkers has been previously 
found (14, 34), suggesting a profound systemic response to blast 
exposure; such distinctive biomarker patterns could be useful in 
differentiating mbTBI from impact TBI and TBI from PTSD.
In our previous study that outlined the main features of our 
experimental model (30), we compared several shockwave forms: 
(1) the Friedländer waveform, a simplified qualitative depiction of 
an explosion-generated shockwave showing positive and negative 
phases of a pressure wave; (2) an open field shockwave generated by 
detonating 816.47 g (1.8 lbs) of a TNT-equivalent explosive charge 
in open field (even terrain, no surrounding objects) conditions. The 
static pressure was recorded 3.6 m from the source; (3) a complex 
shockwave form generated by detonating 725.75 g (1.6 lbs) of a 
TNT-equivalent explosive charge in an urban-environment. The 
static pressure was recorded 2.3  m from the source; and (4) a 
moderate intensity shockwave form generated in our shock tube. 
The static pressure was recorded 4.5 m downstream from the 
shock tube diaphragm. The blast signatures showed a similarity 
between the shapes of the shock tube output and the open field 
shockwave; the intensity of the shock tube-generated overpressure 
has been modified based on the Bowen curve calculations for small 
experimental animals.
In this study, we used our previously standardized mouse 
model of primary blast injuries, generated using a modular, 
multi-chamber shock tube capable of reproducing complex shock 
wave signatures seen in theater (30, 31), to elucidate the molecular 
mechanisms that underlie the neurobehavioral and functional 
deficits observed clinically and modeled experimentally (20, 28, 40, 
41). The experimental set-up in our current study is comparable, 
albeit not identical to the previous design (30). Nevertheless, the 
general response to the blast exposure including BW changes, acute 
neurological recovery, and tissue damage in multiple organs (PSS 
score) is very similar in both studies. This implies that all other 
outcome measures (i.e., behavior, motor, and cognitive function) 
are also comparable in the two studies.
Using antibody-based proteomic analyses, we monitored 
changes in the serum levels of 31 protein biomarkers up to 1-month 
post-injury and identified a number of leading pathologies that 
include metabolic and vascular changes with minimal neuronal 
and glial damage. More specifically, we collected blood samples 
from injured mice at 2-h, 1-day, 1-week, and 1-month post-blast 
to determine the short- and long-term changes in protein markers 
related to metabolism (4-HNE, HIF-1α, ceruloplasmin), vascular 
function (AQP1, AQP4, VEGF, vWF, Flk-1), inflammation (OPN, 
CINC1, fibrinogen, MIP-1α, OX-44, p38, MMP-8, MCP-1 CCR5, 
CRP, galectin-1), cell adhesion and the extracellular matrix (integ-
rin α6, TIMP1, TIMP4, Ncad, connexin-43), axonal (NF-H, Tau), 
neuronal (NSE, CK-BB), and glial damage (GFAP, S100β, MBP).
Clinical observations and experimental studies using differ-
ent TBI models have shown that mTBI is followed by metabolic 
changes, including oxidative stress (8, 42, 43). In this study, we 
found that all three metabolic markers responded to mbTBI with 
rapid and lasting increases. Serum levels of 4-HNE, a byproduct 
of lipid peroxidation, was significantly increased 2 h after injury 
and its levels remained elevated at 1-month post-injury. Previous 
studies of chronic otitis, bipolar disorder, and experimental TBI 
have found associations between elevated serum 4-HNE levels and 
oxidative stress (44–47). HIF1α, a transcription factor, is part of 
organisms’ adaptive response to noxious insults involving brain 
hypoxia (e.g., TBI and stroke); blocking HIF-1α has been found to 
ameliorate neuronal and vascular damage (48–51). Ceruloplasmin 
is involved in facilitating the export of un-bound iron and iron 
metabolism in the brain (52, 53). Iron metabolism in the CNS must 
be tightly regulated as excess iron can lead to metabolic stress. 
TBI causes an elevation of non-heme bound iron independent 
of hemorrhage or microbleeding; excess iron can trigger the pro-
duction of reactive oxygen species leading to oxidative stress and 
inflammation. Therefore, increased ceruloplasmin levels after TBI 
may reflect a compensatory response to injury-induced increases 
in free iron (52).
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Previous data indicated that the exposure to low-intensity blast 
can increase serum levels of biomarkers related to various vascular 
functions (14, 34). The vascular markers we tested in this study, 
especially VEGF and vWF, showed robust changes of differing 
temporal patterns in response to blast. VEGF, a trophic factor 
of endothelial origin, is a key regulator of numerous vascular 
functions such as the regulation of endothelial permeability, micro-
vascular density, and angiogenesis among others (54–56). Hypoxia 
is one of the inducers of VEGF expression, and elevated serum 
levels of VEGF have been associated with various tumors and 
inflammatory processes. We previously found similarly elevated 
serum VEGF levels in other animal models of TBI (14, 34). The 
temporal profile of serum VEGF levels showing a robust and steady 
increase that peaks at 1-month post-injury suggests continuing 
vascular changes with a tendency for chronicity. Such a temporal 
profile may implicate a lasting peripheral/systemic pathological 
response to low-intensity blast in mice.
The importance of the blast-induced hydrodynamic pulse 
through venous vasculature has been demonstrated in recently 
published experimental work by Simard et al. (57). In rats exposed 
to thorax only blast injury, the authors found perivascular, mainly 
perivenular, changes in the brain consistent with neuroinflam-
mation: upregulation of TNF-α accompanied by the finding of 
ED-1-positive cells (macrophages or activated microglia). It has 
been suggested that the hydrodynamic pulse radiates through 
vasculature away from its site of origin, ascending easily into the 
vasculature of the brain via veins since there are no valves to impede 
pressure transmission. The passage of the pressure throughout the 
body, besides its direct effects on the vasculature, also activates the 
autonomous system triggering parasympathetic reflexes causing a 
sudden drop in blood pressure and heart rate as well as intermit-
tent periods of tachypnea and bradypnea. The ensuing hypoxia 
caused either by the vagal reflex loop, lung parenchyma damage, 
or both, further contributes to the changes in systemic and cerebral 
metabolism as well as in vascular tone.
AQP1 serum levels exhibited a temporal profile similar to 
that of VEGF. It was significantly increased at 2  h after injury 
and remained elevated at 1 month. In the CNS, AQP1 is mostly 
expressed by epithelial cells of the choroid plexus; as the major 
water-transporting protein in choroid plexus, it is involved in CSF 
production (58). However, AQP1 is also expressed in several non-
neural cells including epithelial cells of the lung and peritoneum 
among others. (59). Chronically elevated serum levels of AQP1 
can indicate injury to peripheral organs, such as the lungs or the 
GI tract; indeed, their roles have been suggested in the peripheral 
pathomechanism of bTBI (13, 30).
Serum levels of vWF, another marker of vascular/endothelial 
stress/damage, also showed a robust response to injury. vWF, 
an endothelium-specific glycoprotein, is primarily involved in 
restoring homeostasis in response to endothelial stress, recruiting 
platelets, and regulating blood coagulation (60, 61). Similar to 
VEGF, vWF is also involved in the regulation of angiogenesis, cell 
proliferation, and inflammation (61). Elevated vWF serum level is 
an indicator of increased vascular permeability in various disease 
conditions and of unfavorable outcome in TBI (62). Increased 
vWF serum levels have also been found in systemic inflammation 
(63, 64).
Consistent with the increase in vWF, we also found significant 
increases in the serum levels of several inflammatory markers 
in response to low-intensity blast. The levels of OPN remained 
elevated at 1  month after injury indicating that low-intensity 
blast might trigger a chronic inflammatory process. This finding 
is consistent with our previous observation in the same model 
of bTBI, which demonstrated a substantial ongoing systemic 
inflammatory process that included the CNS (30). Elevated OPN 
levels can indicate an autoimmune process as seen in multiple 
sclerosis (65–67).
CINC1 is produced by astrocytes in response to various 
noxious stimuli, including oxidative stress (68). Elevated serum 
levels of fibrinogen, a plasma glycoprotein, are another indication 
of altered microcirculation and inflammation; increased levels 
of fibrinogen can increase blood viscosity as well as vascular 
permeability (69, 70). According to studies showing correlation 
between elevated fibrinogen precursor protein and Alzheimer’s 
disease, elevated fibrinogen levels can link inflammation and 
vascular damage to neurodegeneration. MIP1α is a proinflam-
matory chemokine, and its elevated serum levels are yet another 
indicator of inflammation (71).
Inflammation can also be triggered by injury-induced changes 
in cellular adhesion (72, 73). The transient increase in serum levels 
of cell adhesion/cell surface markers can be an indication of low-
intensity blast’s ability to interrupt cellular connectivity, which 
may in turn contribute to the initiation and/or potentiation of the 
inflammatory response. The blast-induced cell surface disruption 
seems to be transient as shown by the early peaks in integrin α6, 
TIMP1, TIMP4, Ncad, and connexin-43 serum levels. At 1 month 
after injury, levels of TIMP4 and Ncad were back or close to con-
trol values. TIMP4 is an inhibitor of matrix metalloproteinases 
involved in the degradation of the extracellular matrix, thus, cell 
surface remodeling can be part of the response to low-intensity 
blast exposure (74–76). N-cadherin, a multifunctional molecule 
with important roles in cell adhesion, is also involved in mediating 
astrogliosis (77, 78).
The changes in serum protein biomarkers discussed above can 
reflect a systemic or at least partly systemic molecular response 
to blast. Indeed, previous studies have shown that the exposure 
to blast triggers complex systemic responses, including a systemic 
inflammatory response and altered physiological functions (13, 
14, 30). These – and other systemic changes – can contribute 
significantly to the pathomechanisms of mbTBI. In addition to 
the systemic response to blast, we found indications of axonal, neu-
ronal, and glial damage. Our previous works have demonstrated 
that the exposure to a single low-intensity blast can trigger changes 
in the serum levels of markers indicating neuronal and astroglial 
damage (17, 20, 23, 79, 80). A recent clinical study found elevated 
serum levels of ubiquitin C-terminal hydrolase-L1 (UCH-L1), 
αII-spectrin breakdown products (SBDPs), and GFAP in soldiers 
repeatedly exposed to low-intensity explosive blast indicating 
damage to neuronal and glial structural integrity (81).
Serum levels of the neuronal markers NSE and CK-BB were 
only increased during the acute and subacute post-injury period, 
and returned to normal levels at 1 month. Of the two axonal dam-
age markers, the serum levels of NF-H showed rapid and sustained 
increases, whereas Tau levels were increased only during the acute 
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phase of injury (2 h and 1 day). Elevated serum levels of various 
neurofilament proteins have been found to clinically correlate 
with injury severity; as such, they could be useful in predicting 
injury outcome (82). In a large animal model of bTBI, rapid rise of 
serum NF-H levels has been shown to correlate with unfavorable 
outcome (79). Clinically, elevated serum levels of total tau have 
been found to be good and bad predictors of outcome after mTBI 
(83–86). It should be noted that clinical studies typically analyze 
serum levels of protein biomarkers (e.g., tau) at a single – and not 
always at the same – post-injury time point(s). As our current 
study illustrates, serum levels of protein biomarkers change as a 
function of time elapsed after injury. Therefore, a negative finding 
based on a single measurement has little diagnostic (or scientific) 
value. An elegant experimental study has shown that tissue levels of 
various tau proteins, including cleaved and phosphorylated forms, 
were increased at the 24-h post-injury time point and remained 
increased at 30 days in the brains of mice exposed to mild blast 
(87). These finding implicate tau pathology as one of the long-
term consequences of a single mild bTBI, but in the absence of 
serum data it is unclear how intracerebral findings translate into 
changes detectable in the serum. Furthermore, dysfunction of the 
glymphatic pathway (triggered by TBI) can substantially affect the 
intracerebral accumulation of tau and modify its serum levels as 
discussed later (88).
The sustained increase in serum NF-H levels, especially in the 
light of the similarly elevated MBP levels, indicates ongoing white 
matter damage. White matter injury detected by diffusion-tensor 
imaging (DTI) has been identified as a hallmark of mTBI (21, 89, 
90). Indeed, in our current study as well as previous experiments, 
we have found indications of myelin damage reflected by elevated 
serum MBP levels (79). Both experimental and clinical imaging 
studies have found white matter tract damages following blast 
exposure(s) (89, 91, 92). The exact pathology that can cause and or 
sustain long-term axonal damage is currently not fully understood, 
but inflammatory responses have been implicated in the long-term 
effect of bTBI (93).
Of the astroglial markers, only S100β levels increased signifi-
cantly and only at the 1-month time point. Astrogliosis, one of the 
hallmarks of TBI, represents a neuroprotective response to injury 
(94). Intriguingly, GFAP levels did not increase significantly at any 
of the measured time points. These somewhat conflicting find-
ings can be explained by the fact that S100β is a cytoplasmic and 
partially membrane-bound protein, whereas GFAP is a cytoskeletal 
protein. Although the exact relationship between physical forces 
and structural damage at the molecular level is not known, one 
can hypothesize that cytoplasmic proteins can likely be released 
more easily from mildly damaged cells upon physical impact than 
structural proteins such as GFAP. Cytoskeletal proteins may require 
larger physical/kinetic forces to damage the cytoskeletal network as 
well as the cellular membrane to enable the release of GFAP into 
the extracellular space. It should be noted that S100β is not entirely 
astroglia-specific, so the detected increases can be from other 
non-neural cells (95, 96). Nevertheless, clinical observations have 
shown that increased serum S100β levels of non-neural origin are 
typically observed at the earliest post-injury time points, whereas 
the delayed increases in serum S100β are usually of neural origin 
and have been associated with unfavorable outcome in severe TBI 
(97). In contrast to GFAP, MBP levels increased substantially at 
all post-injury time points, and remained close to its peak level at 
1 month after injury. Thus, our findings implicate lasting myelin as 
well as axonal damage in the pathobiology of mbTBI as discussed 
above. These findings are consistent with previous clinical imaging 
studies showing chronic white matter damage in military person-
nel exposed to blast (90, 92).
It has been assumed that the elevated serum levels of neural-
specific protein biomarkers also reflect damage and/or at least 
a temporary opening of the blood–brain barrier (BBB) in TBI. 
BBB opening, however, is associated with moderate or severe TBI, 
and mild TBI typically does not increase BBB permeability. This 
paradox has been solved with the recent discovery of the brain 
glymphatic system (98). In this model, the CSF moving through 
the glymphatic pathway transports biomarkers to the blood via 
the cervical lymphatic system, subsequently ending up in the 
systemic circulation. According to this model, no BBB disruption 
is needed for proteins released from damaged neural cells to reach 
the systemic circulation. However, the brain-to-blood transport of 
protein biomarkers depends on the activity of glymphatic system 
and this activity is regulated by multiple clinically relevant fac-
tors such as sleep deprivation (99). Future experiments analyzing 
injury-induced changes in both the serum and the CSF can provide 
critical information about the relationship between intra- and 
extra-cranial pathologies.
conclusion
The extremely complex nature of blast injuries requires full 
understanding of blast physics and effects, and a model repro-
ducing multiple aspects of blast injuries should be defined with 
particular scientific fidelity to conditions observed in theater. 
Otherwise, a model will lack military and clinical relevance and 
the obtained results might be dangerously misleading (11, 100). 
Thus, we strongly believe that if we aspire to understand the origin 
of blast-induced acute and chronic neurological deficits, we should 
reproduce the injurious environment our soldiers are exposed to as 
close as possible: this also requires reproducing the main response 
mechanisms to blast exposure(s) – systemic, local, and cerebral – as 
reported in clinical studies.
There is a continuing discussion about adequate scaling laws 
that would reliably estimate the exposure conditions causing 
comparable injuries in humans and animals. Many of the new 
suggestions about scaling laws focus on the physical mechanisms 
that determine brain response to blast or differences in properties 
of soft tissues of the head or the major anatomical differences, 
particularly of the skull (101–103). Nevertheless, these approaches 
fail to take into account the specificity of the animals’ physiologi-
cal tolerance toward blast exposure, which often differs from the 
human tolerance. Indeed, the human body can survive relatively 
high blast overpressure without experiencing barotrauma. A 5-psi 
blast overpressure would rupture eardrums in about 1% of subjects, 
whereas the threshold for lung damage occurs at about 15-psi blast 
overpressure and a 35–45 psi overpressure may cause 1% fatalities 
(104). Hence, in our model, we used the Bowen animal-to-human 
scaling laws for blast effects on the animals, which is based on mass 
scaling, to set the basic parameters for shockwave exposure; then, 
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we fine tuned to conditions to reach the clinical features of blast 
injuries and blast-induced traumatic brain injuries described in 
humans exposed to blast (6, 24, 25, 105–107).
Although the research community’s interest is almost entirely 
focused on neurological deficits due to blast, which grouped 
together often called bTBI and a “signature wound” of recent 
wars, accumulating evidence provides more and more support 
to the importance of systemic, multi-organ mechanisms in the 
pathobiology of blast-induced neurological deficits. Bearing this 
in mind, we used the previously developed, well-standardized, 
and validated mouse model of primary blast injuries (30), which 
reproduces the main consequences of blast exposures: changes in 
general physiology, multi-organ damages, systemic compensatory 
mechanisms, as well as neurological deficits seen in individuals 
exposed to differing blast intensity levels. Thus, our intention 
was never to reproduce only a head injury (i.e., isolated TBI) in 
classical terms, but the full spectrum of injury response mecha-
nisms induced by primary blast. These include the autonomous 
system activation including the parasympathic reflexes; hypoxia 
caused either by the vagal reflex loop, lung parenchyma damage 
or both; changes in vascular tonus or systemic and/or cerebral 
metabolism – all these, rather than direct brain parenchyma 
damage, might underlie the blast-induced neurological deficits. 
Indeed, our current data provide further support to the impor-
tance of systemic changes in the pathobiology of blast-induced 
neurological deficits.
In summary, this is the first study to determine the temporal 
pattern of changes in the serum levels of protein biomarkers after 
a single exposure to low-intensity blast in the high-fidelity mouse 
model of bTBI. Our findings implicate oxidative stress, vascular 
changes, inflammation, altered cell adhesion, neuronal, and glial 
damage/loss in the pathobiology of bTBI. The observed temporal 
profiles of markers illustrate the dynamic nature of numerous 
molecular mechanisms related to the systemic and cerebral response 
to blast. Our work is limited by the incomplete understanding of 
the physics of explosive blast, how the physical event translates into 
biological response(s) and importantly, how well rodent models 
replicate the human condition. Proteolytic cleavage of protein 
biomarkers is also a potential issue for Reverse Phase Protein 
Microarray (RPPM) like all other antibody-based systems, such 
as the ELISA, Luminex, or Western blots. Nonetheless, our findings 
underline the importance of monitoring serum biomarker levels 
over a prolonged period of time. Determining the temporal pattern 
of molecular changes can provide critical information about the 
progression or regression of the individual pathomechanisms 
and help in the development of targeted and timely therapeutic 
interventions for improved prognosis.
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